Skip to main content
Terug
SEPN logo

Septerna, Inc.

Datakwaliteit: 100%
SEPN
NASDAQ Healthcare Biotechnology
€ 23,78
▼ € 0,40 (-1,65%)
Marktkapitalisatie: 1,07B
Dagbereik
€ 23,57 € 25,33
52-Weeksbereik
€ 4,66 € 32,63
Volume
287.694
50D / 200D Gem.
€ 26,59 / € 19,96
Vorige Slotkoers
€ 24,18

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -21,9 0,4
P/B 2,8 2,9
ROE % -12,2 3,7
Net Margin % -106,4 3,9
Rev Growth 5Y % 10,0
D/E 0,1 0,2

Koersdoel Analisten

Hold
€ 39,00 +64.0%
Low: € 28,00 High: € 60,00
Forward WPA
-€ 1,64
Omzet Sch.
68 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 -€ 3,61
-€ 5,23 – -€ 2,04
84 M 2
FY2029 -€ 3,52
-€ 5,09 – -€ 1,99
50 M 2
FY2028 -€ 2,73
-€ 3,63 – -€ 1,76
64 M 4

Belangrijkste Punten

Debt/Equity of 0,06 — conservative balance sheet
Generating 109,67M in free cash flow
PEG of 0,30 suggests growth is underpriced
Capital efficient — spends only 1,13% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)4174,51%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-12,19%
ROIC-14,94%
Net Margin-106,37%
Op. Margin-175,83%

Veiligheid

Debt / Equity
0,06
Current Ratio4,73
Interest Coverage0,00

Waardering

P/E Ratio
-21,85
P/B Ratio2,80
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4174,51% Revenue Growth (3Y) 1644,45%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 45,95M Net Income (TTM) -48,88M
ROE -12,19% ROA -8,20%
Gross Margin 96,51% Operating Margin -175,83%
Net Margin -106,37% Free Cash Flow (TTM) 109,67M
ROIC -14,94% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,06 Current Ratio 4,73
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -21,85 P/B Ratio 2,80
P/S Ratio 23,24 PEG Ratio 0,30
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,07B Enterprise Value 970,78M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue 45,95M 1,08M 151.000,0 0,0
Net Income -48,88M -71,80M 4,18M -27,68M
EPS (Diluted) -1,10 -7,26 0,03 -1,42
Gross Profit 44,35M 1,08M 151.000,0 0,0
Operating Income -80,80M -80,82M 2,08M -27,97M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 596,19M 456,55M 130,87M 36,12M
Total Liabilities 214,26M 36,51M 169,24M 80,32M
Shareholders' Equity 381,93M 420,05M -38,37M -44,20M
Total Debt 23,63M 25,48M 12,57M 710.000,0
Cash & Equivalents 120,72M 238,20M 88,48M 30,61M
Current Assets 410,96M 356,82M 112,68M 31,89M
Current Liabilities 86,93M 12,85M 6,91M 5,54M